Page 58 - Haematologica March 2020

P. Pignatelli et al.
bodies detected in two different assay sys-
tems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005;93(2):289-297.
58. Tonello M, Mattia E, Favaro M, et al. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphos- pholipid antibody carriers. Thromb Res. 2019;177:157-160.
59. Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional informa- tion in patients with thrombosis? Immunobiology. 2007;212(7):557-565.
60. Zigon P, Perdan Pirkmajer K, Tomsic M, et al. Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. J Immunol Res. 2015;2015:975704.
61. Ganapati A, Goel R, Kabeerdoss J, et al. Study of clinical utility of antibodies to phosphatidylserine/prothrombin complex in Asian-Indian patients with suspected APS. Clin Rheumatol. 2019;38(2):545-553.
62. Zigon P, Podovsovnik A, Ambrozic A, et al. Added value of non-criteria antiphospho- lipid antibodies for antiphospholipid syn- drome: lessons learned from year-long rou- tine measurements. Clin Rheumatol. 2019;38(2):371-378.
63. Singh NK, Yadav DP, Gupta A, Singh U, Godara M. Role of anti-annexin A5 in pathogenesis of hypercoagulable state in patients with antiphospholipid syndrome. Int J Rheum Dis. 2013;16(3):325-330.
64. de Laat B, Derksen RH, Mackie IJ, et al. Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis. 2006;65(11):1468-1472.
65. Wolgast LR, Arslan AA, Wu XX, et al. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-posi- tive patients with adverse clinical outcomes. J Thromb Haemost. 2017;15(7):1412-1421.
66. Scholz P, Auler M, Brachvogel B, et al. Detection of multiple annexin autoantibod- ies in a patient with recurrent miscarriages,
fulminant stroke and seronegative antiphos- pholipid syndrome. Biochem Med (Zagreb). 2016;26(2):272-278.
67. Sciascia S, Cosseddu D, Montaruli B, Kuzenko A, Bertero MT. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011;70(8):1517-1518.
68. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504- 512.
69. Oku K, Amengual O, Atsumi T. Antiphospholipid scoring: significance in diagnosis and prognosis. Lupus. 2014;23 (12):1269-1272.
70. Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013;52(8):1397- 1403.
for the prevention of recurrent thrombosis in patients with the antiphospholipid anti- body syndrome. N Engl J Med. 2003;349 (12):1133-1138.
76. Keeling D, Mackie I, Moore GW, et al. Guidelines on the investigation and manage- ment of antiphospholipid syndrome. Br J Haematol. 2012;157(1):47-58.
77. Cohen H, Efthymiou M, Isenberg DA. Use of direct oral anticoagulants in antiphospho- lipid syndrome. J Thromb Haemost. 2018;16(6):1028-1039.
78. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371.
79. Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboem- bolism in the presence of thrombophilia: Findings from RE-COVER(R), RE-COVER II, and RE-MEDY. Vasc Med. 2016;21(6):506-
71. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-
Arruza I, et al. Evidence-based recommen- 514.
dations for the prevention and long-term management of thrombosis in antiphospho- lipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-218.
72. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the man- agement of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296- 1304.
73. Bala MM, Paszek E, Lesniak W, et al. Antiplatelet and anticoagulant agents for pri- mary prevention of thrombosis in individu- als with antiphospholipid antibodies. Cochrane Database Syst Rev. 2018;7: CD012534.
74. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S.
75. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin
80. Woller SC, Stevens SM, Kaplan DA, et al. Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). Clin Appl Thromb Hemost. 2016;22(3):239-247.
81. Canaud G, Bienaime F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371(4):303-312.
82. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphos- pholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685-696.
83. Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-beta2glycopro- tein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18(11):1011-1014.
84. Billoir P, Miranda S, Abboud J, et al. [Which place of antiphosphatidylethanolamine anti- bodies research in seronegative antiphos- pholipid syndrome suspicion?]. Rev Med Interne. 2019;40(6):351-354.
572
haematologica | 2020; 105(3)